Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Inspire Pharma Denufosol Phase 3 TIGER-2 trial fails to meet primary endpoint
The primary endpoint of the trial was change from baseline in FEV1 (Forced Expiratory Volume in One Second) at the Week 48 Endpoint (48 weeks or last observation
The primary endpoint of the trial was change from baseline in FEV1 (Forced Expiratory Volume in One Second) at the Week 48 Endpoint (48 weeks or last observation
Lunesta, a sedative, also called a hypnotic, is used to treat insomnia and causes relaxation to help you fall asleep and stay asleep.The suit settlement allows Lupin to
As a beginning to this relationship, Ecron Acunova has contracted first clinical research study at Newcastle University. Ecron Acunova CRO is a CRO in India and continental Europe,
As per the agreement, CVS Caremark will acquire all of the outstanding stock of Universal American and concurrently distribute to Universal American shareholders 100% of the shares of
ESENSE1 is a 24-week efficacy study, and SENSE, a 52-week safety study, were designed to investigate efficacy and safety of 20mg nalmefene taken ‘as needed’ versus placebo in
Vital Images is a provider of visualization and analysis software for physicians and healthcare specialists. The company’s software provides users productivity and communication tools to improve patient care
Sildenafil is an US Food and Drug Administration (FDA) approved drug used in the treatment of male Erectile Dysfunction (ED). The FDA said that the undeclared ingredient may
The company’s decision follows the Food and Drug Administration (FDA)verdict that the weight loss dietary supplements sold and marketed contains an undeclared drug ingredient. All lots of the
Doryx is a tetracycline-class antibacterial indicated for rickettsial infections, sexually transmitted infections, respiratory tract infections, specific bacterial infections, ophthalmic infections, anthrax, including inhalational anthrax (post-exposure), alternative treatment for
The total purchase price is $80m, consisting of a cash payment of $28.1m at closing, and a 7-year subordinated unsecured promissory note of $51.9m. The acquisition enables SPI